Details:
SAR445229 (amlitelimab) is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, potential to be a first-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-to-severe atopic dermatitis and asthma.
Lead Product(s): Amlitelimab
Therapeutic Area: Dermatology Product Name: SAR445229
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
In study, amlitelimab showed improvements in symptoms of moderate-to-severe atopic dermatitis with well-tolerated safety profile in adults whose disease can not be controlled with topical medications or for whom topical medications are not a recommended treatment approach.
Lead Product(s): Amlitelimab
Therapeutic Area: Dermatology Product Name: SAR445229
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axillary hyperhidrosis.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: ET-01
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Eirion Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2021
Details:
Cedirogant (ABBV-157) is an orally available retinoic acid-related orphan receptor gamma (RORγ) inverse-agonist, small molecule for the treatment of chronic plaque psoriasis.
Lead Product(s): Cedirogant
Therapeutic Area: Dermatology Product Name: ABBV-157
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination October 31, 2022
Details:
It follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical trial with cedirogant (ABBV-157), an oral RORγ inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.
Lead Product(s): Cedirogant
Therapeutic Area: Dermatology Product Name: ABBV-157
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $4.3 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 31, 2022